ArticleFrontiers in immunology2021
Bortezomib Sustains T Cell Function by Inducing miR-155-Mediated Downregulation of SOCS1 and SHIP1.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 38 citations in OpenAlex.
- Targeting the non-coding RNA-PANoptosis axis: a novel frontier in disease diagnosis and therapy.Apoptosis : an international journal on programmed cell death · 2026Review
- Enhancing Proteasome Activity in T Cells Alleviates Exhaustion and Improves Antitumor Immunity.Cancer research · 2026Article
- Exosomal MicroRNAs as Drivers of Desmoplasia and Treatment Resistance in Breast Cancer: Mechanisms, Biomarker Potential, and Therapeutic Opportunities.Biomolecules · 2026Review
- The SHIP1-inflammatory-lipid axis in Alzheimer's disease: from genetic risk to spatiotemporal mechanistic insights.Journal of neuroinflammation · 2026Review
- The Role of Non-coding RNAs in Connective Tissue Diseases: Diagnostic and Therapeutic Potential of miRNAs, lncRNAs and circRNAs.Molecular diagnosis & therapy · 2026Review
- MicroRNA-targeted reprogramming of CD8+ T cells against cancer.Frontiers in immunology · 2026Review
- Regulatory T cell dysfunction and exhaustion in uveitis: immunometabolic mechanisms, microenvironmental drivers, and emerging therapeutic strategies.Frontiers in immunology · 2026Review
- miR-142-5p promotes TSCM differentiation and suppresses progressive T-cell maturation via targeting PRKCB.Frontiers in immunology · 2026Article
- Diagnostic and prognostic value of miR-155 in non-cystic fibrosis bronchiectasis.BMC pulmonary medicine · 2025Article
- Inhibition of microRNA-155 regulates gastric mucosal barrier repair and inflammation by targeting SOCS1 for the treatment of acute gastritis.Scientific reports · 2025Article
- Elevated miRNA-21, miRNA-155, and miRNA-182 levels correlate with cytokine dysregulation in neurological disorders and indicate potential for biomarker and therapy development.Scientific reports · 2025Article
- Epigenetic regulation of the tumor microenvironment in lung cancer: mechanism insights and therapeutic prospects.Frontiers in immunology · 2025Review
- Unraveling the interplay of CD8 + T cells and microRNA signaling in cancer: implications for immune dysfunction and therapeutic approaches.Journal of translational medicine · 2024Review
- Combination of bortezomib and venetoclax targets the pro-survival function of LMP-1 and EBNA-3C of Epstein-Barr virus in spontaneous lymphoblastoid cell lines.PLoS pathogens · 2024Article
- SARS-CoV-2-Specific T Lymphocytes Analysis in mRNA-Vaccinated Patients with B-Cell Lymphoid Malignancies on Active Treatment.Vaccines · 2024Article
- Reactive oxygen species/glutathione dual sensitive nanoparticles with encapsulation of miR155 and curcumin for synergized cancer immunotherapy.Journal of nanobiotechnology · 2024Article
- MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways.Cancer cell international · 2024Review
- Treatment of multiple myeloma: What is the impact on T-cell function?Therapeutic advances in hematology · 2024Review
- MicroRNAs: Small but Key Players in Viral Infections and Immune Responses to Viral Pathogens.Biology · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Ariana N RenrickDepartment of Microbiology, Immunology and Physiology, School of Medicine, Meharry Medical College, Nashville, TN, United States.
Menaka C ThounaojamDepartment of Biochemistry, Cancer Biology, Neuroscience and Pharmacology, School of Medicine, Meharry Medical College, Nashville, TN, United States.
Maria Teresa P de AquinoDepartment of Biochemistry, Cancer Biology, Neuroscience and Pharmacology, School of Medicine, Meharry Medical College, Nashville, TN, United States.
Evan ChaudhuriDepartment of Microbiology, Immunology and Physiology, School of Medicine, Meharry Medical College, Nashville, TN, United States.
Jui PandhareDepartment of Microbiology, Immunology and Physiology, School of Medicine, Meharry Medical College, Nashville, TN, United States.
Chandravanu DashSchool of Graduate Studies and Research, Meharry Medical College, Nashville, TN, United States.
Anil ShankerSchool of Graduate Studies and Research, Meharry Medical College, Nashville, TN, United States.
Meharry Medical College · USVanderbilt University · US
Funding
The RCMI Program in Health Disparities Research at Meharry Medical College - SupplementU54MD007586 · NIMHD · MEHARRY MEDICAL COLLEGE · PI SANIKA SAMUEL CHIRWA · 2017 to 2026
$48.2MTennessee CFAR: Implementation of Culturally Responsive Trauma-Informed Care with Youth with HIV in Memphis, TNP30AI110527 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI John Koethe · 2015 to 2026
$27.5MTechnologies and Resources CoreU54MD007593 · NIMHD · MEHARRY MEDICAL COLLEGE · PI ADUNYAH, SAMUEL EVANS · 2012 to 2018
$24.7MTranslational Pathology CoreU54CA163069 · NCI · MEHARRY MEDICAL COLLEGE · PI ADUNYAH, SAMUEL EVANS, STEWART, LAMONICA VANETTE · 2011 to 2025
$18.8MResearch Training in Cardivascular Biology at MeharryT32HL007737 · NHLBI · MEHARRY MEDICAL COLLEGE · PI MARTIN, PAMELA M · 1993 to 2025
$4.7MRole of Fus1-mediated antitumor CD8T-NK crosstalk in Alzheimer's disease pathologySC1CA182843 · NCI · MEHARRY MEDICAL COLLEGE · PI SHANKER, ANIL · 2013 to 2020
$3.1MThe effect of HIV and cocaine abuse on semen exosome composition and functionR01DA042348 · NIDA · UNIVERSITY OF IOWA · PI OKEOMA, CHIOMA M · 2016 to 2020
$2.7MMethamphetamine Research Program at Meharry Medical CollegeR24DA036420 · NIDA · MEHARRY MEDICAL COLLEGE · PI CHARLTON, CLIVEL G. · 2014 to 2018
$2.3MRole of the Viral Capsid in HIV-1 IntegrationR01AI136740 · NIAID · MEHARRY MEDICAL COLLEGE · PI Chandravanu Dash · 2019 to 2026
$2.2MNotch ligands in regulation of anti-cancer immunityR01CA175370 · NCI · OHIO STATE UNIVERSITY · PI CARBONE, DAVID P., DIKOV, MIKHAIL M · 2013 to 2017
$1.6MRole of the Viral Capsid in HIV-1 Integration.R56AI122960 · NIAID · MEHARRY MEDICAL COLLEGE · PI DASH, CHANDRAVANU · 2016 to 2016
$376kNCI NIH HHS R01 CA175370NCI NIH HHS SC1 CA182843NCI NIH HHS U54 CA163069NHLBI NIH HHS T32 HL007737NIAID NIH HHS P30 AI110527NIAID NIH HHS R01 AI136740NIAID NIH HHS R56 AI122960NIDA NIH HHS R01 DA042348NIDA NIH HHS R24 DA036420NIMHD NIH HHS U54 MD007593
Abstract
Suppressive mechanisms operating within T cells are linked to immune dysfunction in the tumor microenvironment. We have previously reported using adoptive T cell immunotherapy models that tumor-bearing mice treated with a regimen of proteasome inhibitor, bortezomib - a dipeptidyl boronate, show increased antitumor lymphocyte effector function and survival. Here, we identify a mechanism for the improved antitumor CD8
Indexed as
AnimalsAntineoplastic AgentsBortezomibCD8-Positive T-LymphocytesCell Line, TumorCytokinesDisease Models, AnimalGene Expression Regulation, NeoplasticHumansLymphocyte CountMiceMicroRNAsPhosphatidylinositol-3,4,5-Trisphosphate 5-PhosphatasesProteasome InhibitorsRNA FoldingRNA InterferenceAntineoplastic AgentsBortezomibCytokinesInpp5d protein, mouseMicroRNAsMirn155 microRNA, mousePhosphatidylinositol-3,4,5-Trisphosphate 5-PhosphatasesProteasome InhibitorsSocs1 protein, mouseSuppressor of Cytokine Signaling 1 Proteinantitumor immunitycancer immunotherapyimmunomodulatorsimmunosuppressionlymphocyte functionmicroRNAT cell exhaustiontumor microenvironment
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.